According to The Insight Partners' research, the North America Vaccines Market was valued at US$ 34,058.6 Million in 2024 and is expected to reach US$ 50,877.2 Million by 2031, registering a CAGR of 5.9% from 2025 to 2031.
Surging immunization programs, government initiatives, and development of combination and therapeutic vaccines are among the critical factors attributed to drive the North America vaccines market growth.
Immunization programs offer services that ensure immunity to vaccine-preventable diseases. These services include documenting evidence of immunity, administering immunizations and re-immunizations, and maintaining records for reporting to state or local immunization information systems (IIS), also known as vaccine registries.
The Essential Programme for Immunization (EPI), developed by WHO, was designed to coordinate the targeted implementation of vaccination through national immunization programs. This initiative has been instrumental in expanding global vaccine access. Additionally, the establishment of Gavi, the Vaccine Alliance, an independent multilateral funding mechanism in 2000, aimed at increasing global access to vaccines, has played a critical role in facilitating vaccine introduction in low- and middle-income countries (LMICs). According to an article published in the Journal of Infectious Diseases in October 2021, it is estimated that vaccine access has prevented at least 37 million deaths in 98 LMICs by protecting against 10 vaccine-preventable diseases, including Haemophilus influenzae type B, Japanese encephalitis, Neisseria meningitidis serogroup A, measles, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever.
The World Health Assembly, with the support of various countries and partners, launched a strategy called the Immunization Agenda 2030 in 2020. This initiative aims to address vaccination challenges and save over 50 million lives by 2030. In the US, vaccination initiatives are diverse and include federal programs like the Vaccines for Children program, as well as state and local efforts and partnerships with various organizations. These programs aim to increase vaccination rates, ensure equitable access to vaccines, and combat diseases that can be prevented through vaccination.
On the contrary, high vaccine development cost and increased time to market hampers the growth of the North America vaccines market.
North America Vaccines Market Segmentation Analysis:
- By Type, the North America Vaccines Market is segmented into Conjugated Vaccines, Inactivated Vaccines, Live Vaccines, Recombinant Vaccines, and Toxoid Vaccines. The Conjugated segment is projected to expand at a CAGR of 6.6% during 2025 - 2031.
- By Indication, the North America Vaccines Market is segmented into HPV, PCV, DTP, Hepatitis, Influenza, Dengue, and Other. The HPV segment is projected to expand at a CAGR of during 2025 - 2031.
- By Route of Administration, the North America Vaccines Market is segmented into Injection, Oral, and Other. The Injection segment is projected to expand at a CAGR of 5.7% during 2025 - 2031
- By Age Group, the North America Vaccines Market is segmented into Pediatric and Adult. The Pediatric segment is projected to expand at a CAGR of 6.1% during 2025 - 2031
By country, the North America Vaccines Market is categorized into the United States, Canada, and Mexico. The United States is projected to expand at a CAGR of 6.0% during 2025 - 2031.
Key players operating in the Vaccines Market are Abbott Laboratories, GSK Plc, Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi SA, CSL Ltd, Serum Institute of India Pvt Ltd, BioNTech SE, and Sinovac Biotech Ltd, among others.
In October 2024, Pfizer's RSV vaccine, ABRYSVO, was approved by the U. S. FDA for adults aged 18 to 59 who are at higher risk for respiratory diseases caused by RSV. This vaccine provides the widest indication for adults, extending beyond those aged 60 and older. It is also the only RSV vaccine approved for pregnant women between 32 and 36 weeks of gestation, helping protect infants from birth to 6 months.
In July 2022, GSK announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com